These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34450472)

  • 1. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
    Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
    Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dynamics of more-than-human care in depot buprenorphine treatment: A new materialist analysis of Australian patients' experiences.
    Barnett A; Pienaar K; Lubman DI; Arunogiri S; Phan V; Hayes V; Lintzeris N; Savic M
    Int J Drug Policy; 2024 May; 127():104399. PubMed ID: 38636315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
    Johnson B; Monwell B; Capusan AJ
    Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.
    Allen E; Samadian S; Altobelli G; Johnson J; Holmwood C
    Drug Alcohol Rev; 2023 May; 42(4):791-802. PubMed ID: 36788357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences.
    Neale J; Tompkins CNE; Strang J
    Drug Alcohol Rev; 2019 Jul; 38(5):510-518. PubMed ID: 31131514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings.
    Dunlop AJ; White B; Roberts J; Cretikos M; Attalla D; Ling R; Searles A; Mackson J; Doyle MF; McEntyre E; Attia J; Oldmeadow C; Howard MV; Murrell T; Haber PS; Lintzeris N
    Addiction; 2022 Feb; 117(2):382-391. PubMed ID: 34184798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
    Tompkins CNE; Neale J; Strang J
    J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depot.
    Treloar C; Lancaster K; Gendera S; Rhodes T; Shahbazi J; Byrne M; Degenhardt L; Farrell M
    Int J Drug Policy; 2022 Sep; 107():103788. PubMed ID: 35816790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.
    Clay S; Treloar C; Degenhardt L; Grebely J; Christmass M; Gough C; Hayllar J; McDonough M; Henderson C; Crawford S; Farrell M; Marshall A
    Int J Drug Policy; 2023 May; 115():104002. PubMed ID: 37003194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Matters-of-concern' associated with discontinuation of long-acting injectable buprenorphine: Findings from a longitudinal qualitative study.
    Parkin S; Neale J; Strang J
    Int J Drug Policy; 2024 Jul; 129():104470. PubMed ID: 38843737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions.
    Tran AD; Chen R; Nielsen S; Zahra E; Degenhardt L; Santo T; Farrell M; Larance B
    Int J Drug Policy; 2022 Jan; 99():103472. PubMed ID: 34649203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model.
    Ling R; White B; Roberts J; Cretikos M; Howard MV; Haber PS; Lintzeris N; Reeves P; Dunlop AJ; Searles A
    BMC Health Serv Res; 2022 Nov; 22(1):1326. PubMed ID: 36348369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study.
    Larance B; Byrne M; Lintzeris N; Nielsen S; Grebely J; Degenhardt L; Shahbazi J; Shanahan M; Lancaster K; Dore G; Ali R; Farrell M;
    BMJ Open; 2020 Jul; 10(7):e034389. PubMed ID: 32737087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration and patient-incurred costs associated with opioid agonist treatment in Norway.
    Pedersen MH; Danø A; Gibbons C; Jensen R
    Curr Med Res Opin; 2022 Nov; 38(11):1959-1965. PubMed ID: 36172758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.
    Larance B; Degenhardt L; Grebely J; Nielsen S; Bruno R; Dietze P; Lancaster K; Larney S; Santo T; Shanahan M; Memedovic S; Ali R; Farrell M
    Addiction; 2020 Jul; 115(7):1295-1305. PubMed ID: 31860767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
    Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the advent of depot therapy represent a step change in our understanding of opioid use disorder and its treatment?
    Roberts E; Humphreys K
    Drug Alcohol Rev; 2024 Jan; 43(1):261-264. PubMed ID: 37525510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.